Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Fampridine-SR 50mg/Day	104
Overall Study	STARTED	Placebo	100
Overall Study	Intent to Treat (ITT) Population	Fampridine-SR 50mg/Day	103
Overall Study	Intent to Treat (ITT) Population	Placebo	100
Overall Study	Safety Population	Fampridine-SR 50mg/Day	103
Overall Study	Safety Population	Placebo	100
Overall Study	Efficacy Population	Fampridine-SR 50mg/Day	89
Overall Study	Efficacy Population	Placebo	93
Overall Study	COMPLETED	Fampridine-SR 50mg/Day	78
Overall Study	COMPLETED	Placebo	88
Overall Study	NOT COMPLETED	Fampridine-SR 50mg/Day	26
Overall Study	NOT COMPLETED	Placebo	12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01683838/flow